196 related articles for article (PubMed ID: 21775819)
1. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
3. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
[TBL] [Abstract][Full Text] [Related]
5. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
6. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Gemignani F; Landi S
Int J Biol Markers; 2011; 26(2):117-23. PubMed ID: 21574151
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
9. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.
Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V; Franko A
Radiol Oncol; 2020 Mar; 54(1):86-95. PubMed ID: 32187018
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
[TBL] [Abstract][Full Text] [Related]
13. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
15. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
16. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population.
Yu M; Zhang Y; Jiang Z; Chen J; Liu L; Lou J; Zhang X
Environ Health Prev Med; 2015 Sep; 20(5):369-78. PubMed ID: 26188910
[TBL] [Abstract][Full Text] [Related]
18. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
19. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S
PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798
[TBL] [Abstract][Full Text] [Related]
20. Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.
Paajanen J; Sadek A; Richards WG; Xie Y; Mazzola E; Sidopoulos K; Kuckelman J; Gill RR; Bueno R
Thorac Cancer; 2024 May; 15(15):1237-1245. PubMed ID: 38627917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
